ARTICLE | Company News
Trimeris, Roche infectious diseases news
August 19, 2002 7:00 AM UTC
The companies said they began physician enrollment in a U.S. early access program for the companies' Fuzeon enfuvirtide ( T-20) HIV fusion inhibitor. The access program initially will be available to...